Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins

DOI Web Site Web Site PubMed 被引用文献2件 参考文献17件
  • Zhang Fan
    Biological Engineering Institute of Zhejiang Chinese Medical University
  • Liu Mu-rong
    BIODOOR Biotechnology Co., Ltd. of Hangzhou City in Zhejiang Province
  • Wan Hai-tong
    Biological Engineering Institute of Zhejiang Chinese Medical University

この論文をさがす

説明

PEGylation changes the physical and chemical properties of the biomedical molecule, such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug, while it also causes some disadvantages of which cannot be neglected. The available data manifests that polyethylene glycol (PEG) itself shows potential risk, such as immunogenicity of the PEG and PEG-containing vacuoles in cells observed with PEGylated biologicals. Decreased activity and heterogeneity are also the negative aspects of PEGylation. The unfavorable impacts which are brought by the PEGylation are described here with examples of modified therapeutic proteins on the market and used in the clinical trials.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (17)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ